// App-Quantinova.ai

P1-12-05 : First-Line Chemotherapy with Pegylated Liposomal Doxorubicin Versus Capecitabine in Elderly Patients with Metastatic Breast Cancer: Results of the Phase III OMEGA Study of the Dutch Breast Cancer Trialists- Group (BOOG)

Researchers

Presenter

  • Smorenburg CH

Principal Investigators

  • Seynaeve C

  • Wymenga MANM

  • van Tinteren H

  • de Groot SM

  • van Leeuwen-Stok EAE

  • Nortier HWR

  • Maartense E

  • de Graaf H

  • de Jongh FE

  • Braun HJ

  • Los M

  • Schrama JG

  • Portielje JEA

  • Hamaker M

Medical Centers

  • Vlietland Hospital, Schiedam, Netherlands

  • Medical Center Alkmaar, Alkmaar, Netherlands

  • St Antonius Hospital, Nieuwegein, Netherlands

  • Comprehensive Cancer Center The Netherlands, Utrecht, Netherlands

  • Reinier de Graaf Groep, Delft, Netherlands

  • Antoni van Leeuwenhoek - NKI (Netherlands Cancer Institute), Amsterdam, Netherlands

  • Diakonessenhuis, Utrecht, Netherlands

  • Dutch Breast Cancer Trialists Group, Amsterdam, Netherlands

  • Haga Hospitals, Den Haag, Netherlands

  • Medisch Spectrum Twente, Enschede, Netherlands

  • Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Doxorubicin Hydrochloride

  • Capecitabine

  • Doxorubicin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved